Based on this study, the PD-L1 immunohistochemistry (IHC) 22C3 PharmDx test (Dako, Agilent, Santa Clara, CA, USA) was approved by the US Food and Drug Administration (FDA) concurrently with pembrolizumab for patients with gastric cancer (GC). Here, CD274 is linked to gastric cancer.